Article

Forbes on 2020-05-21 14:00

How Eli Lilly’s Investors Cashed In 90% Capital Gains While Sales Barely Moved?

Eli Lilly’s stock moved nearly 90% between 2016 and 2019 even though the company barely had any revenue growth to show for it. So what got Eli Lilly’s ...

Related news

FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab Forbes
A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1 Forbes
Poland , Krakow
FDA Authorizes Eli Lilly’s Covid Antibody Therapy For Emergency Use In Young Children Forbes
Eli Lilly’s Compliance Head on ‘Capturing Hearts’blogs.wsj.com
Eli Lilly’s Profit Dented by Higher Costs wsj.com
Eli Lilly’s New Compliance Chief on His Priorities6 min read wsj.com
Canada
US OKs new use for Eli Lilly’s COVID-19 treatment bangordailynews.com
Indianapolis
Forbes Daily: Weight Loss Drugs Fuel Eli Lilly’s Ascent Forbes
Tribunal dismisses Eli Lilly’s NAFTA challenge on promise utility doctrine jdsupra.com
Canada , Free Trade
Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern The New York Times
Veterans Affairs
MEli Lilly’s therapy with solanezumab didn’t decelerate the illness mvtelegraph.com
Brigham City
Eli Lilly’s EFFIENT combination use patent found obvious jdsupra.com
California , United States , Switzerland
Eli Lilly’s sees strength in 2017, shares take off seattletimes.com
FHigh stakes: Eli Lilly’s hunt for an Alzheimer’s drug ft.com
South East Asia , China
Eli Lilly’s Experimental Alzheimer’s Drug Fails in Large Trial The New York Times
FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug Forbes
Eli Lilly’s promising Alzheimer’s drug fails in clinical trials FOX 8 News Cleveland
Indiana , Indianapolis
BEli Lilly’s Earnings Raise Hopes for Pharmaceutical Stocks barrons.com
IEli Lilly’s (LLY) diabetes injection Mufenda gets approval in China invezz.com
China